- In January 2022, to deliver non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR business, QIAGEN formed partnerships with Atila BioSystems
- In June 2021, Next-generation genomics and Illumina Thailand has launched the VeriSeq NIPT Solution v2, a next-generation sequencing (NGS)-based solution that helps detect anomalies missed by targeted tests
Frequently Asked Questions
The market is segmented based on Global Non-invasive Prenatal Testing Market Segmentation, By Product and Services (Products, Services), Method (Ultrasound Detection, Biochemical Screening Test, Cell-Free DNA in Maternal Plasma Tests), Application (Trisomy, Microdeletion Syndrome, Other), End-User (Diagnostic Laboratories, Hospitals), Test Type (Materni21, Harmony, Panorama, Verify, NIFTY, Others), Technology (NGS, WGS, Others) – Industry Trends and Forecast to 2032
.
The Global Non Invasive Prenatal Testing Market size was valued at USD 4.75 USD Billion in 2024.
The Global Non Invasive Prenatal Testing Market is projected to grow at a CAGR of 13.8% during the forecast period of 2025 to 2032.
The major players operating in the market include IlluminaInc. , Thermo Fisher Scientific Inc. , General Electric , BGI Group AGilent TechnologiesInc. , F. Hoffmann-La Roche Ltd. , PerkinElmer Inc. , Laboratory Corporation of America Holdings , NateraInc. , Yourgene Health , Eurofins LifeCodexx GmbH , Quest Diagnostics Incorporated , Myriad Genetics Inc. , NIPD Genetics , Next Biosciences .
The market report covers data from the .
